PRLX Pengajuan SEC - Parallax Health Sciences Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1388410

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Parallax Health Sciences Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

May 12, 2022	8-K	Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IRS
May 12, 2022	EX-10	Hyperlinks have been added for ease of navigation. EXHIBIT 10.1 Note: Certain Exhibits to the Intellectual Property Purchase Agreement may make reference to Agreements as Exhibits, all of which are included herein. Redundant Exhibits are omitted. Hyperlinks have been added for ease of navigation. CONTENTS INTELLECTUAL PROPERTY PURCHASE AGREEMENT PURCHASED ASSETS SENIOR SECURED CORPORATE PROMISSORY NOTE INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGR
March 28, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IR
September 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number)
September 29, 2021	EX-10	between Parallax Health Sciences, Inc and EXECUTIVE AGREEMENT This Executive Agreement (?Agreement?), effective September 14, 2021 (the ?Effective Date?), is executed on September 14, 2021 by and between Parallax Health Sciences, Inc.
August 31, 2021	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IRS
August 23, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number)
July 13, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IRS
July 13, 2021	8-K/A	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IR
April 8, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission File Number) (IRS
June 29, 2020	NT 10-Q	- FORM NT-10Q Form NT-10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report o
May 20, 2020	10-K/A	Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-52534 PARALLAX HEALTH SCIENCES, INC. (Exact n
May 18, 2020	10-K	Annual Report - ANNUAL REPORT 12-31-2019 Annual Report 12-31-2019 UNITED STATES SECURITIES AD EXCHANGE COMMISSION Washington, D.
May 18, 2020	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
May 15, 2020	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
April 15, 2020	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
April 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
April 9, 2020	EX-10	Executive Agreement between Parallax Health Sciences and Landis Enterprises, LLC dated March 1, 2020 Ex 10.1 Executive Agreement-DL Stark EXECUTIVE AGREEMENT This Executive Agreement (“Agreement”), effective March 1, 2020 (the “Effective Date”), is executed on April 7, 2020, by and between Parallax Health Sciences, Inc., a Nevada corporation, (the ‘Company”), located at 1327 Ocean Avenue, Suite B, Santa Monica, CA 90401, and Landis Enterprises LLC, a Delaware limited liability company, located at
March 30, 2020	EX-99	FREEDMAN & GOLDBERG CERTIFIED PUBLIC ACCOUNTANTS A PROFESSIONAL CORPORATION STATEMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Ex 99.1 Statement from Freedman & Goldberg CPAs FREEDMAN & GOLDBERG CERTIFIED PUBLIC ACCOUNTANTS A PROFESSIONAL CORPORATION STATEMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Parallax Health Sciences, Inc. On March 4, 2020, the Governor of the State of California issued an Executive Order N-33-20 to proclaim a State of Emergency to exist in Cal
March 30, 2020	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
March 13, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
March 13, 2020	EX-3	Certificate of Amendment to Articles of Incorporation dated March 5, 2020 Ex 3.1 Certificate of Amendment STATE OF NEVADA BARBARA K. CEGAVSKE Commercial Recordings Division Secretary of State 202 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138 KIMBERLEY PERONDI • North Las Vegas City Hall Deputy Secretary for 2250 Las Vegas Blvd North, Suite 400 OFFICE OF THE Commercial Recordings North Las Vegas, NV 89030 SECRETARY OF STATE Telephone
March 12, 2020	EX-99	Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform Company will Partner to Accelerate the Deployment of Diagnostic Solutions Under Patent Protected Service Area Ex 99.1 Press Release dated 03/11/2020 Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform Company will Partner to Accelerate the Deployment of Diagnostic Solutions Under Patent Protected Service Areas Including China, Hong Kong, India and US NEW YORK, New York March 11, 2020 Parallax Health Sciences, Inc. (OT
March 12, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
February 21, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
February 14, 2020	EX-3	Certificate of Designation-Series B1 Preferred Stock Ex 3.1 Certificate of Designation-Series B1 STATE OF NEVADA BARBARA K. CEGAVSKE Commercial Recordings Division Secretary of State 202 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138 KIMBERLEY PERONDI • North Las Vegas City Hall Deputy Secretary for 2250 Las Vegas Blvd North, Suite 400 OFFICE OF THE Commercial Recordings North Las Vegas, NV 89030 SECRETARY OF STAT
February 14, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
February 14, 2020	DEFR14A	PRLX / Parallax Health Sciences Inc. DEFR14A - - FORM DEF-14A-AMENDMENT NO 1 Form Def-14a-Amendment 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 14, 2020	DEF 14A	PRLX / Parallax Health Sciences Inc. DEF 14A - - FORM DEF-14A Form Pre-14a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
February 14, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
February 14, 2020	EX-10	Securities Purchase Agreement dated February 10, 2020 Ex 10.1 Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 10, 2020, between Parallax Health Sciences, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, s
February 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
February 3, 2020	PRE 14A	PRLX / Parallax Health Sciences Inc. PRE 14A - - FORM PRE-14A 01-31-2020 Form Pre-14a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
January 30, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
December 23, 2019	424B4	PARALLAX HEALTH SCIENCES, INC. 32,583,436 Shares of Common Stock Form S-1/A #5 Registration Filed Pursuant to Rule 424(b)(3) Registration No. 333-231981 December 23, 2019 PARALLAX HEALTH SCIENCES, INC. 32,583,436 Shares of Common Stock This prospectus relates to the resale of up to 32,583,436 shares of Parallax Health Sciences, Inc., a Nevada corporation (the “Company”), Common Stock, par value $0.001 per share (“Common Stock”), including 14,633,436 outstanding
December 20, 2019	CORRESP	PRLX / Parallax Health Sciences Inc. CORRESP - - SEC Acceleration Request VIA EDGAR December 20, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Registration Statement on Form S-1 File No. 333-231981 REQUEST FOR ACCELERATION OF EFFECTIVENESS Dear Ms. Lam: Pursuant to Rule 461 pro
December 13, 2019	10-Q/A	PRLX / Parallax Health Sciences Inc. 10-Q/A - Quarterly Report - QUARTERLY REPORT-06-30-19 AMENDMENT NO. 2 Quarterly Report 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 13, 2019	10-Q/A	PRLX / Parallax Health Sciences Inc. 10-Q/A - Quarterly Report - QUARTERLY REPORT 09-30-19-AMENDMENT NO. 1 Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
December 13, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. BY EDGAR AND FEDERAL EXPRESS December 12, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amended Form 10-K for the Fiscal Year ended December 31, 2018 Filed November 26, 2019 File No. 000-52534 Dear Ms. Lam: By letter dated Decemb
December 13, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 5 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46- Form S-1/A #5 Registration File No. 333-231981 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 5 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard Industrial (IRS Employer of Incorporation)
December 13, 2019	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 5 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSI Annual Report 12-31-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 13, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. SEC Response Letter-S-1 BY EDGAR AND FEDERAL EXPRESS December 13, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amendment No. 4 to Registration Statement on Form S-1 Filed December 2, 2019 File No. 333-231981 Dear Ms. Lam: By let
December 2, 2019	EX-4	Description of Oral Agreements to Extend Maturities of Certain Convertible Promissory Notes EX-4 3 ex420descriptionoforal.htm EX 4.20 DESCRIPTION OF ORAL AGREEMENT PARALLAX HEALTH SCIENCES, INC. DESCRIPTION OF ORAL AGREEMENTS TO EXTEND MATURITIES OF CERTAIN CONVERTIBLE PROMISSORY NOTES In September 2017 and March 2018, the Company issued convertible promissory notes (the “Notes”) in the aggregate principal of $91,000 (“Investor Group A”) and $20,000 (“Lender Group A”), respectively. The
December 2, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 4 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46- Form S-1/A #4 Registration File No. 333-231981 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard Industrial (IRS Employer of Incorporation)
December 2, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. SEC Response Letter-S-1 BY EDGAR AND FEDERAL EXPRESS December 2, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed November 14, 2019 File No. 333-231981 Dear Ms. Lam: By let
November 26, 2019	EX-4	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K EX-4 9 ex411secpurchagreemt.htm EX 4.11 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 2, 2019, by and between PARALLAX HEALTH SCIENCES, INC., a Nevada corporation, with its address at 1327 Ocean Avenue, Suite B, Santa Monica, CA 90401 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with
November 26, 2019	EX-3	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K. Ex 3.4 Certificate of Amendment-Name Change '♦&♦~♦ ' ROSS MILLER 090203 Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Profit
November 26, 2019	EX-3	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K. BARBARA K. CEGAVSKE 090503 Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Filed in the office of Document Number WN..K. 20190030247-18 Barbara K. Cegavske Filing Date and Time Certificate to Accompany Secretary of State 01/23/2019 3:05 PM State of Nevada Entity Number Restated Articles or E0427292005-7 Amended and Restated Articles
November 26, 2019	EX-3	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K PARALLAX HEALTH SCIENCES, INC. CERTIFICATE OF VALIDATION March 11, 2019 This Certificate of Validation (this “Certificate”) is filed on behalf of Parallax Health Science, Inc., a Nevada corporation (the “Corporation”), pursuant to Section 78.0296 of the Nevada Revised Statutes (“NRS”), which provides that, if a corporate act ratified or validated pursuant to such section would have required any fi
November 26, 2019	EX-4	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K EX-4 8 ex410convpromnote.htm EX 4.10 CONVERTIBLE PROMISSORY NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE
November 26, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. BY EDGAR AND FEDERAL EXPRESS November 26, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amended Form 10-K for the Fiscal Year ended December 31, 2018 Filed October 21, 2019 File No. 000-52534 Dear Ms. Lam: By letter dated Novembe
November 26, 2019	EX-3	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K PARALLAX HEALTH SCIENCES, INC. CERTIFICATE OF VALIDATION March 11, 2019 This Certificate of Validation (this “Certificate”) is filed on behalf of Parallax Health Science, Inc., a Nevada corporation (the “Corporation”), pursuant to Section 78.0296 of the Nevada Revised Statutes (“NRS”), which provides that, if a corporate act ratified or validated pursuant to such section would have required any fi
November 26, 2019	EX-3	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K PARALLAX HEALTH SCIENCES, INC. CERTIFICATE OF VALIDATION March 11, 2019 This Certificate of Validation (this “Certificate”) is filed on behalf of Parallax Health Science, Inc., a Nevada corporation (the “Corporation”), pursuant to Section 78.0296 of the Nevada Revised Statutes (“NRS”), which provides that, if a corporate act ratified or validated pursuant to such section would have required any fi
November 26, 2019	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 4 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSI Annual Report 12-31-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 26, 2019	EX-4	Filed with the SEC on November 26, 2019 as part of the Company's Annual Report on Form 10-K EX-4 10 ex417debtsettlement.htm EX 4.17 DEBT SETTLEMENT June 4, 2019 ███████████ ███████████ ███████████ ███████████ ███████████ ███████████ ███████████ ███████████ Re: Debt Settlement & Warrant Retirement Gents: This letter when countersigned by you on behalf of the convertible debenture holdings of Parallax Health Sciences, Inc., (the “Company”) held by ███████████ and ███████████ (the “Investor
November 18, 2019	10-Q	PRLX / Parallax Health Sciences Inc. 10-Q - Quarterly Report - QUARTERLY REPORT 09-30-2019 Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
November 18, 2019	EX-99	Parallax Health Sciences Reports Third Quarter 2019 Financial Results Company Increases Revenues by More Than 700% and Reduces Operating Loss by 10% Over Prior Year Nine Months Period EX-99 2 ex991pressreleaseq3.htm EX 99.1 PRESS RELEASE DATED 11/18/2019 Parallax Health Sciences Reports Third Quarter 2019 Financial Results Company Increases Revenues by More Than 700% and Reduces Operating Loss by 10% Over Prior Year Nine Months Period SANTA MONICA, CALIF. (November 18, 2019) - Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax”), an outcome-driven connected healthcare comp
November 18, 2019	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
November 15, 2019	NT 10-Q	PRLX / Parallax Health Sciences Inc. NT 10-Q - - FORM NT-10Q Form NT-10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Repo
November 14, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46- Form S-1/A #2 Registration File No. 333-231981 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard Industrial (IRS Employer of Incorporation)
November 14, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. BY EDGAR AND FEDERAL EXPRESS November 13, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed October 30, 2019 File No. 333-231981 Dear Ms. Lam: By letter dated November 4, 20
October 31, 2019	EX-4	Filed with the SEC on October 16, 2019 as part of the Company's Current Report on Form 8-K NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THIS PROMISSORY NOTE ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
October 31, 2019	EX-4	Filed with the SEC on October 16, 2019 as part of the Company's Current Report on Form 8-K Note: October 23, 2019 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.
October 31, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
October 30, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. BY EDGAR AND FEDERAL EXPRESS October 29, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 29, 2019 File No. 333-231981 Dear Ms. Lam: By letter dated August 8, 2019, th
October 30, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 2 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46- File No. 333-231981 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard Industrial (IRS Employer of Incorporation) Classification Code Number
October 25, 2019	10-Q/A	Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5253
October 24, 2019	10-K/A	ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 3 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year end December 31, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0
October 23, 2019	EX-10	Employment Agreement between Parallax Health Sciences, Inc. and David Appell dated April 19, 2019 Ex 10.1 Employment Agreement-David Appell EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”), dated April 19, 2019 and made effective the earlier of May 15, 2019 or the initial closing of $1.25 million of escrow from the current $6 million finance offering, (the Employment Start Date”), is entered into by and between Parallax Health Sciences, Inc. (“the Company”), a Nevada corporation, (
October 23, 2019	10-Q	PRLX / Parallax Health Sciences Inc. 10-Q - Quarterly Report - QUARTERLY REPORT Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
October 21, 2019	EX-10	Executive Agreement between Parallax Health Sciences, Inc. and MJ Management Services, Inc FSO Calli R. Bucci dated January 1, 2018 EXECUTIVE AGREEMENT This Executive Agreement (“Agreement”), effective January 1, 2018, is executed on January 20, 2019, by and between Parallax Health Sciences, Inc.
October 21, 2019	EX-10	Filed with the SEC on October 21, 2019 as part of the Company's amended Annual Report on Form 10-K/A SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 27, 2019, is entered into by and between PARALLAX HEALTH SCIENCES, INC.
October 21, 2019	EX-10	Exchange Agreements dated December 31, 2018 between Parallax Health Sciences, Inc. and, Cavalry Fund LLP, DiamondRock, LLC, The Corbran LLC, and Digital Power Lending, LLC EX-10 4 ex1041exchangeagreements.htm EX 10.41 EXCHANGE AGREEMENTS EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 31st day of December and effective November 14, 2018, by and between, Parallax Health Sciences, Inc., a Nevada corporation, (the “Company”) and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”). WHEREAS, the Investor has previously acquir
October 21, 2019	EX-10	Employment Agreement between Parallax Health Sciences, Inc., and Nathaniel T. Bradley dated August 1, 2017 Ex 10.44 Employment Agreement-N Bradley EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”), dated November 30, 2017, made effective August 1, 2017, is entered into by and between Parallax Health Sciences, Inc. (“the Company”), a Nevada corporation, (the ‘Employer”), and Nathaniel T. Bradley, 4200 S. Saguaro Path Court, Tucson, AZ 85730 (the “Employee”). WITNESSETH: WHEREAS, Employer is e
October 21, 2019	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSI Annual Report 12-31-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 21, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. SEC Response Letter-10-K BY EDGAR AND FEDERAL EXPRESS October 21, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Amended Form 10-K for the Fiscal Year ended December 31, 2018 Filed July 26, 2019 File No. 000-52534 Dear Ms. Lam: By
October 21, 2019	EX-10	Letter Agreements dated December 31, 2018 between Parallax Health Sciences, Inc. and, Cavalry Fund LLP, DiamondRock, LLC, The Corbran LLC, and Digital Power Lending, LLC Cavalry Fund I LP 61 Kinderkamack Road Woodcliff Lake, NJ 07677 December 31, 2018 VIA EMAIL: paul@parallaxcare.
October 16, 2019	EX-10	Purchase Agreement between Parallax Health Sciences, Inc. and Global Center Networks dated August 28, 2019 PURCHASE AGREEMENT This PURCHASE AGREEMENT (this “Agreement”) is dated as of August 28, 2019, (“Effective Date”) between Global Career Networks Inc.
October 16, 2019	EX-99	Parallax Health Sciences Announces Acquisition Of Minority Interest In Global Career Networks Ex 99.1 Press Release dated 09-19-2019 Parallax Health Sciences Announces Acquisition Of Minority Interest In Global Career Networks SANTA MONICA, Calif. (September 19, 2019) Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announces it has entered into a strategic transaction agreement with Global Career Networks
October 16, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets 8-K 1 20191016form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or othe
October 2, 2019	EX-16	Exhibit 16.1 Ex 16.1 Letter From Former CPA
October 2, 2019	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissi
August 14, 2019	NT 10-Q	PRLX / Parallax Health Sciences Inc. NT 10-Q - - FORM NT-10Q Form NT-10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on
July 29, 2019	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) S-1/A 1 amendment1forms1prlx.htm FORM S-1 REGISTRATION-AMENDMENT 1 File No. 333 -231981 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard I
July 29, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. SEC Response Letter-S-1 BY EDGAR AND FEDERAL EXPRESS July 26, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Registration Statement on Form S-1 Filed June 6, 2019 File No. 333-231981 Dear Ms. Lam: By letter dated July 1, 2019, the
July 26, 2019	EX-10	Exchange Agreements dated December 31, 2018 between Parallax Health Sciences, Inc. and, Cavalry Fund LLP, DiamondRock, LLC, The Corbran LLC, and Digital Power Lending, LLC Ex 10.41 Exchange Agreements
July 26, 2019	EX-10	Letter Agreements dated December 31, 2018 between Parallax Health Sciences, Inc. and, Cavalry Fund LLP, DiamondRock, LLC, The Corbran LLC, and Digital Power Lending, LLC Ex 10.40 Letter Agreements
July 26, 2019	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSI Annual Report 12-31-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 26, 2019	CORRESP	PARALLAX HEALTH SCIENCES, INC. Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. ● Parallax Diagnostics, Inc. ● Parallax Communications, Inc. BY EDGAR AND FEDERAL EXPRESS July 26, 2019 Ms. Joanna Lam United States Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F Street, N.E. Washington, D.C. 20549 RE:Parallax Health Sciences, Inc. Form 10-K for the Fiscal Year ended December 31, 2018 Filed April 1, 2019 File No. 000-52534 Dear Ms. Lam: By letter dated July 1, 2019, the staf
July 26, 2019	EX-10	Filed with the SEC on July 26, 2019 as part of the Company's amended Annual Report on Form 10-K/A Ex 10.42 Securities Purchase Agreements
July 23, 2019	CORRESP	PRLX / Parallax Health Sciences Inc. CORRESP - - CORRESP-Extension on SEC Comments Response Filed by Edgar Correspondence July 23, 2019 Ms.
July 19, 2019	EX-16	Exhibit 16.1 Ex 16.1 Letter from Former CPA
July 19, 2019	8-K	Current Report 8-K 1 20190717form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other ju
July 11, 2019	EX-4	Filed with the SEC on July 12, 2019 as part of the Company's Current Report on Form 8-K Ex 4.1 Form of Senior Secured Note THE OFFER AND SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE. THIS NOTE AND ANY SECURITIES ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN A
July 11, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
July 11, 2019	EX-10	Filed with the SEC on July 12, 2019 as part of the Company's Current Report on Form 8-K Ex 10.1 Form of Note and Purchase Agreement NOTE AND PURCHASE AGREEMENT This Note and Purchase Agreement (this “Agreement”) is dated as of July 3, 2019 among PARALLAX HEALTH SCIENCES, INC., a Nevada corporation with its principal place of business located at 1327 Ocean Avenue Suite B, Santa Monica CA 90401 (the “Company”), and and the other purchasers, if any, identified on the signature pages her
June 17, 2019	EX-10	Filed with the SEC on June 17, 2019, as part of the Company’s Registration Statement on Form S-8 Ex 10.1 2019 Stock Incentive Plan PARALLAX HEALTH SCIENCES, INC. 2019 STOCK INCENTIVE PLAN 1.PURPOSE1 2.DEFINITIONS1 3.ADMINISTRATION4 4.ELIGIBILITY5 5.COMMON STOCK SUBJECT TO PLAN5 6.OPTIONS5 7.STOCK AWARDS8 8.CHANGES IN CAPITAL STRUCTURE10 9.WITHHOLDING OF TAXES10 10.REPURCHASE RIGHTS11 11.COMPLIANCE WITH LAW AND APPROVAL OF REGULATORY BODIES11 12.GENERAL PROVISIONS12 13.AMENDMENT AND TERMINATIO
June 17, 2019	S-8	PRLX / Parallax Health Sciences Inc. S-8 - - FORM S-8 Form S-8 As filed with the U.S. Securities and Exchange Commission on June 17, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 4
June 11, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 333-231981 46-4733512 (State or other jurisdiction (Commission Fi
June 11, 2019	EX-10	Filed with the SEC on June 11, 2019 as part of the Company's Current Report on Form 8-K Ex 4.1 Debt Settlement & Warrant Retirement
June 6, 2019	S-1	Registration Statement on Form S-1 (File No. 333-231981) filed with the Commission on June 6, 2019 Form S-1 Registration File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant as specified in our charter) Nevada 8000 46-4733512 (State or other jurisdiction (Primary Standard Industrial (IRS Employer of Incorporation) Classification Code Number)
May 10, 2019	10-Q	Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
May 7, 2019	EX-4	Filed with the SEC on May 7, 2019 as part of the Company's Current Report on Form 8-K SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 6, 2019, between Parallax Health Sciences, Inc.
May 7, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 20190507form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other juri
May 7, 2019	EX-4	Filed with the SEC on May 7, 2019 as part of the Company's Current Report on Form 8-K Ex 4.3 Warrant NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
May 7, 2019	EX-4	Filed with the SEC on May 7, 2019 as part of the Company's Current Report on Form 8-K EX-4 3 ex42registrationrightsagreem.htm EX 4.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 6, 2019, between Parallax Health Sciences, a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”
April 18, 2019	EX-4	Filed with the SEC on April 19, 2019 as part of the Company's Current Report on Form 8-K Ex 10.1 Securities Purchase Agreement NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE RE
April 18, 2019	EX-10	Filed with the SEC on April 19, 2019 as part of the Company's Current Report on Form 8-K Ex 10.1 Securities Purchase Agreement NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUA
April 18, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
April 18, 2019	EX-10	Form of Securities Purchase Agreement dated April 8, 2019 Ex 10.1 Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 8, 2019, is entered into by and between PARALLAX HEALTH SCIENCES, INC., a Nevada corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreem
April 8, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
April 8, 2019	EX-4	Filed with the SEC on April 9, 2019 as part of the Company’s Current Report on Form 8-K Ex 4.1 12% Convertible Promissory Note
April 8, 2019	EX-10	Filed with the SEC on April 9, 2019 as part of the Company’s Current Report on Form 8-K Ex 10.1 Securities Purchase Agreement
April 1, 2019	EX-3	Filed with the SEC on April 1, 2019, as part of the Company's Annual Report on Form 10-K. Ex 3.1(b) Amended and Restated Articles of Incorporation
April 1, 2019	10-K	Annual Report on Form 10-K for the year ended December 31, 2018 Annual Report 12-31-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 29, 2019	8-K	Regulation FD Disclosure Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
March 29, 2019	EX-99	Filed with the SEC on April 1, 2019 as part of the Company's Current Report on Form 8-K Ex 99.1 Investor Presentation
March 22, 2019	EX-4	Filed with the SEC on March 22, 2019 as part of the Company's Current Report on Form 8-K EXHIBIT A Note: March 18, 2019 NEITHER THESE SECURITI ES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.
March 22, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
March 22, 2019	EX-10	Filed with the SEC on March 22, 2019 as part of the Company's Current Report on Form 8-K Ex 10.1 Warrant Agreement NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURS
March 19, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
March 19, 2019	EX-3	Filed with the SEC on March 19, 2019 as part of the Company's Current Report on Form 8-K Ex 3.6 Cert of Designation-Series A
March 19, 2019	EX-3	Filed with the SEC on March 19, 2019 as part of the Company's Current Report on Form 8-K Ex 3.7 Cert of Designation-Series B
March 19, 2019	EX-3	Filed with the SEC on March 19, 2019 as part of the Company's Current Report on Form 8-K Ex 3.8 Cert of Designation-Series C
March 15, 2019	EX-4	Filed with the SEC on March 15, 2019 as part of the Company's Current Report on Form 8-K EX-4 2 ex41convertiblenote.htm EX 4.1 CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A
March 15, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
March 15, 2019	EX-10	Filed with the SEC on March 15, 2019 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
March 15, 2019	EX-10	Filed with the SEC on March 15, 2019 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 27, 2019, is entered into by and between PARALLAX HEALTH SCIENCES, INC.
March 11, 2019	10-Q/A	Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A #2 (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
February 5, 2019	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
January 29, 2019	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2019 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
January 19, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 20190115form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other
January 8, 2019	DEF 14C	PRLX / Parallax Health Sciences Inc. DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☑ Definitive Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) PARALLAX HEALTH SCIENCES, INC. (Name
January 7, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
January 7, 2019	EX-10	Filed with the SEC on January 7, 2019 as part of the Company's Current Report on Form 8-K EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 31st day of December and effective November 14, 2018, by and between, Parallax Health Sciences, Inc.
January 7, 2019	EX-4	Filed with the SEC on January 7, 2019 as part of the Company's Current Report on Form 8-K CONVERTIBLE DEBENTURE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
January 7, 2019	EX-10	Filed with the SEC on January 7, 2019 as part of the Company's Current Report on Form 8-K Note Holder Name And Address December 31, 2018 Parallax Health Sciences, Inc. 1327 Ocean Avenue, Suite B Santa Monica CA 90401 Attention: Paul R. Arena Re:Amendment to Promissory Note Dear Mr. Arena: This letter agreement (this “Agreement”) by and between Parallax Health Science, Inc. (the “Company”) and (“Note Holder”) acknowledges that effective November 14, 2018, the parties hereto agree to ame
December 26, 2018	PRE 14C	PRLX / Parallax Health Sciences Inc. PRE 14C INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE PRE 14C INFORMATION Preliminary Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☑ Preliminary Information Statement ☐ Definitive Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) PARALLAX HEALTH SCIE
November 23, 2018	EX-4	Filed with the SEC on November 26, 2018 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF
November 23, 2018	EX-4	Filed with the SEC on November 26, 2018 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz SIGNING DEBENTURE NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
November 23, 2018	EX-10	Equity Purchase Agreement between Parallax Health Sciences, Inc., and Peak One Opportunity Fund LP dated November 14, 2018 Converted by EDGARwiz EQUITY PURCHASE AGREEMENT This equity purchase agreement is entered into as of November 14, 2018 (this "Agreement"), by and between Parallax Health Sciences, Inc.
November 23, 2018	EX-4	Filed with the SEC on November 26, 2018 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of November 14, 2018, by and between PARALLAX HEALTH SCIENCES, INC.
November 23, 2018	EX-10	Securities Purchase Agreement between Parallax Health Sciences, Inc., and Peak One Opportunity Fund LP dated November 14, 2018 Converted by EDGARwiz SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 14, 2018, is entered into by and between PARALLAX HEALTH SCIENCES, INC.
November 23, 2018	EX-4	Filed with the SEC on November 26, 2018 as part of the Company's Current Report on Form 8-K Converted by EDGARwiz SIGNING DEBENTURE NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
November 23, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
November 16, 2018	EX-99	Parallax Health Sciences Reports Third Quarter Financial Results Liabilities from continuing operations reduced by $24.5 million in Q3, and $18.2 million net income year-to-date Company positioned for future success with breakeven from operations exp Parallax Health Sciences Reports Third Quarter Financial Results Liabilities from continuing operations reduced by $24.
November 16, 2018	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
November 16, 2018	EX-100.DEF	PRLX / Parallax Health Sciences Inc. XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
November 16, 2018	EX-100.SCH	000830 - Disclosure - Warrants And Options: Options, Current Period Grants (Details) link:presentationLink link:definitionLink link:calculationLink 00
November 16, 2018	EX-100.LAB	PRLX / Parallax Health Sciences Inc. XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
November 16, 2018	EX-100.INS	PRLX / Parallax Health Sciences Inc. XBRL INSTANCE DOCUMENT
November 16, 2018	EX-100.CAL	PRLX / Parallax Health Sciences Inc. XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
November 16, 2018	10-Q/A	Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000
November 16, 2018	EX-100.PRE	PRLX / Parallax Health Sciences Inc. XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
November 15, 2018	10-Q	Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
September 28, 2018	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
September 20, 2018	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
September 10, 2018	10-K/A	PRLX / Parallax Health Sciences Inc. AMENDMENT-ANNUAL REPORT 12-31-17 (Annual Report) ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year end December 31, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534 PARALLA
September 10, 2018	10-K	PRLX / Parallax Health Sciences Inc. ANNUAL REPORT 12-31-2017 (Annual Report) Annual Report 12-31-2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 31, 2018	10-Q/A	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5253
August 31, 2018	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
August 29, 2018	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
August 27, 2018	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
July 11, 2018	EX-4	2015 Incentive Compensation Plan Ex 4.7 2015 Incentive Compensation Plan Exhibit 4.7 PARALLAX HEALTH SCIENCES, INC. 2015 INCENTIVE COMPENSATION PLAN PARALLAX HEALTH SCIENCES, INC. 2015 INCENTIVE COMPENSATION PLAN 1) Purpose. The purpose of this PARALLAX HEALTH SCIENCES, INC. 2015 INCENTIVE COMPENSATION PLAN (the “Plan”) is to assist Parallax Health Sciences, Inc., a Nevada corporation (the “Company”) and its Operating Subsidiarie
July 11, 2018	10-K	PRLX / Parallax Health Sciences Inc. ANNUAL REPORT 12-31-2016 (Annual Report) Annual Report 12-31-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 11, 2018	EX-4	2016 Incentive Compensation Plan Ex 4.8 2016 Incentive Compensation Plan Exhibit 4.8 PARALLAX HEALTH SCIENCES, INC. 2016 INCENTIVE COMPENSATION PLAN PARALLAX HEALTH SCIENCES, INC. 2016 INCENTIVE COMPENSATION PLAN 1) Purpose. The purpose of this PARALLAX HEALTH SCIENCES, INC. 2016 INCENTIVE COMPENSATION PLAN (the “Plan”) is to assist Parallax Health Sciences, Inc., a Nevada corporation (the “Company”) and its Operating Subsidiarie
June 22, 2018	EX-10	Form Note and Purchase Agreement dated June 18, 2018 Ex 10.1 Note and Purchase Agreement NOTE AND PURCHASE AGREEMENT This Note and Purchase Agreement (this “Agreement”) is dated as of June 18, 2018 among PARALLAX HEALTH SCIENCES, INC., a Nevada corporation with its principal place of business located at 1327 Ocean Avenue, Suite B, Santa Monica CA 90401 (the “Company”), and with an address at and the other purchasers, if any, identified on the signat
June 22, 2018	EX-10	Form Amendment to Note Purchase Agreement and Note dated June 18, 2018 Ex 10.2 Form of Amedment to Note and Purchase Agreement AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT AND NOTE PARALLAX HEALTH SCIENCES, INC. THIS FIRST AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT AND NOTE (the “Amendment”) is executed as of this day of June, 2018 (the “Effective Date”) by and between Parallax Health Sciences, Inc., a Nevada corporation, with its principal o
June 22, 2018	EX-4	Exhibit 4.3 Ex 4.3 Form of Piggyback Registration Rights PIGGY-BACK REGISTRATION RIGHTS AGREEMENT PIGGY-BACK REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 18, 2018, by and between Parallax Health Sciences, Inc., a Nevada corporation (the “Company”), and , (the “Holder”). RECITALS: 1. Pursuant to the Purchase Agreement of even date herewith and the other Transaction Documents (as defined i
June 22, 2018	EX-4	Form of Security Agreement dated June 18, 2018 Ex 4.2 Form of Security Agreement SECURITY AGREEMENT This Security Agreement (“Agreement”) is made and entered into as of June 18, 2018, by and between PARALLAX HEALTH SCIENCES, INC., a Nevada corporation with its principal place of business located at 1327 Ocean Avenue Suite B, Santa Monica CA 90401 (the “Debtor”), and with an address at and the other purchasers, if any, identified on the signatu
June 22, 2018	EX-10	Form of Warrant Agreement dated June 18, 2018 Ex 10.3 Form of Warrant Agreement THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. 2018- Number of Shares: 6,000,000 (subject to adjustment) Date of Issuance: June 18, 2018 Original Issue Date (as defined in subsection 2(a)(I)(B)): June 18, 2018 PARALLAX HEALTH SCIENCES, INC. Common S
June 22, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
June 22, 2018	EX-10	Form of Amendment to Warrant Agreement dated June 18, 2018 EX-10 8 ex104formofwarrantamend.htm EX 10.4 FORM OF WARRANT AMENDMENT AMENDMENT TO WARRANT AGREEMENT THIS FIRST AMENDMENT TO THE WARRANT AGREEMENT dated June , 2018, by and between Parallax Health Sciences, Inc., a Nevada corporation, with its principal office at 1327 Ocean Ave., Suite M, Santa Monica, CA 90401, (the “Company”) and , (the “Registered Holder”) is hereby amended as follows with the
June 22, 2018	EX-4	Form of 12% Senior Secured Convertible Note dated June 18, 2018 Ex 4.1 Form of Note THE OFFER AND SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE. THIS NOTE AND ANY SECURITIES ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMP
June 14, 2018	8-K	Current Report Current Repoort UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
May 18, 2018	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2018 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
December 13, 2017	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2017 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
December 13, 2017	EX-16	Exhibit 16.8 Ex 16.8 Letter from CPA DAVE BANERJEE, CPA An Accountancy Corporation ? Member AICPA and PCAOB 6301 Owensmouth Avenue, Suite 750, Woodland Hills, CA 91367l (818) 657-0288l FAX (818) 657-0299l (818) 312-3283 December 12, 2017 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements included under Item 4.01
November 29, 2017	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
October 4, 2017	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
September 21, 2017	10-Q	PRLX / Parallax Health Sciences Inc. QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
July 27, 2017	EX-10	Employment Agreement between Parallax Health Sciences, Inc., and Paul R. Arena dated July 1, 2017 Ex 10.37 Employment Agreement-Arena EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”), effective July 1, 2017, is entered into by and between Parallax Health Sciences, Inc. (“the Company”), a Nevada corporation, (the ‘Employer”), and Paul R. Arena, P.O. Box 4407, Huntington, NY 11743 (the “Employee”). WITNESSETH: WHEREAS, Employer is engaged in the pharmacy, diagnostics technology, beha
July 27, 2017	10-K	PRLX / Parallax Health Sciences Inc. ANNUAL REPORT 12-31-2015 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-52534 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant a
July 13, 2017	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement Current Report Amendment No 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 12, 2017	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2017 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
May 4, 2017	EX-10	Consulting Agreement between Parallax Health Sciences, Inc., and James Gaynor dated April 27, 2017 Ex 10.34 Consulting Agreement CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) dated as of the day of April, 2017 between Parallax Behavioral Health, Inc. (the ?Company?), a Nevada corporation at 1327 Ocean Ave, Suite M, Santa Monica, CA 90401 and James G. Gaynor, II, an individual at [removed] (the ?Consultant?) The Company and Consultant are individually a ?Party? to this Agreem
May 4, 2017	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2017 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
May 4, 2017	EX-10	Intellectual Property Purchase Agreement between Parallax Health Sciences, Inc., Parallax Behavioral Health, Inc., and ProEventa Inc. dated April 27, 2017 Ex 10.33 IP Purchase Agreement INTELLECTUAL PROPERTY PURCHASE AGREEMENT by and among PARALLAX BEHAVIORAL HEALTH, INC., PARALLAX HEALTH SCIENCES, INC., AND PROEVENTA, INC. This INTELLECTUAL PROPERTY PURCHASE AGREEMENT, dated as of April 27, 2017 (this ?Agreement?), by and among ProEventa, Inc., a Delaware corporation (?Seller?), on the one hand, and Parallax Behavioral Health, Inc., a Delaware corp
March 20, 2017	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2017 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission F
January 4, 2017	8-K	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2016 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
October 15, 2016	10-Q/A	Parallax Health Sciences QUARTERLY REPORT-AMENDMENT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000
October 13, 2016	10-Q	Parallax Health Sciences QUARTERLY REPORT (Quarterly Report) Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
September 28, 2016	8-K	Current Report Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 23, 2016	EX-10	License Royalty Agreement between La Frontera Community Solutions, Inc. and QOLPOM Inc. dated August 29, 2016 Converted by EDGARwiz LICENSE ROYALTY AGREEMENT Effective August 29, 2016 (the ?Effective Date?) La Frontera Community Solutions, Inc.
September 23, 2016	EX-10	Assignment Agreement between La Frontera Community Solutions, Inc. and QOLPOM Inc. dated August 25, 2016 Converted by EDGARwiz
September 23, 2016	EX-2	Agreement to Purchase and Sell 100% of Qolpom, Inc, and Its Assets, Intellectual Property and Inventory dated August 31, 2016 Converted by EDGARwiz AGREEMENT TO PURCHASE AND SELL ONE HUNDRED PERCENT (100%) OF THE ISSUED AND OUTSTANDING SHARES OF QOLPOM, INC.
September 23, 2016	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 13, 2016	8-K	Current Report Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2016	8-K/A	Current Report Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2015 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commissio
March 31, 2016	NT 10-K	Parallax Health Sciences EXTENSION Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 18, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 18, 2015	EX-16	16.1 Letter from former certifying public accountant. UNITED STATES SEALE and BEERS, CPAs PCAOB REGISTERED AUDITORS www.sealebeers.com November 18, 2015 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements included under Item 4.01 in the Form 8-K dated October 29, 2015 of Parallax Health Sciences, Inc. (the "Company") to be filed with the Securities and E
November 16, 2015	NT 10-Q	Parallax Health Sciences EXTENSION Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 19, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 2, 2015	CORRESP	Parallax Health Sciences ESP Correspondence
August 24, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534 PARALLAX HEALTH
August 20, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
August 19, 2015	EX-10	EMPLOYMENT AGREEMENT Ex 10.32 Employment Agreemet-Melamed EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made effective as of August 13, 2015 by and between Shahla Melamed, a California resident (?Shana? or ?Melamed?), RoxSan Pharmacy, Inc., a California corporation (?RoxSan?), and Parallax Health Sciences, Inc., a publicly traded Nevada corporation (the ?Company?). WHEREAS, Melamed owns all of the ou
August 19, 2015	EX-2	Filed with the SEC on August 18, 2015 as part of the Company's Current Report on Form 8-K. Ex 2.3 Purchase Agreement AGREEMENT TO PURCHASE AND SELL ONE HUNDRED PERCENT (100%) OF THE ISSUED AND OUTSTANDING SHARES OF ROXSAN PHARMACY, INC. AND ITS ASSETS AND INVENTORY THIS AGREEMENT TO PURCHASE AND SELL ONE HUNDRED PERCENT (100%) OF THE ISSUED AND OUTSTANDING SHARES OF ROXSAN PHARMACY, INC. AND ITS ASSETS AND INVENTORY (?Agreement?) is made as of August 13, 2015 (the ?Effective Date?) by a
August 19, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2015 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission
August 17, 2015	NT 10-Q	Parallax Health Sciences EXTENSION TO FILE Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 6, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2015 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
July 24, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2015 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fi
June 3, 2015	8-K	Parallax Health Sciences CURRENT REPORT (Current Report/Significant Event) Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2015 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction (Commission Fil
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534 PARALLAX HEALTH
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT UNDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-52534 PARALLAX HEALTH SCIENCES, INC. (Exact name of registrant a
December 8, 2014	8-K	Current Report Current Report 12-05-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or o TRANSITION R Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
November 14, 2014	NT 10-Q	PRLX / Parallax Health Sciences Inc. NT 10-Q - - EXTENSION TO FILE Parallax Health Sciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K
August 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534 PARALLAX HEALTH S
August 14, 2014	NT 10-Q	PRLX / Parallax Health Sciences Inc. NT 10-Q - - EXTENSION TO FILE Parallax Health Sciences Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 18, 2014	8-K	8-K Parallax Health Sciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2014 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdictio
May 20, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or o TRANSITION REPOR Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52534
May 14, 2014	NT 10-Q	- PRLX 03-31-14 FORM NT-10-Q PRLX 03-31-14 Form NT-10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 21, 2014	8-K	- CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2014 PARALLAX HEALTH SCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 000-52534 46-4733512 (State or other jurisdiction of Incorporation) (Commissio
April 15, 2014	EX-3	Filed with the SEC on April 15, 2014 as part of the Company’s Annual Report on Form 10-K. Converted by EDGARwiz
April 15, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT UNDER Parallax Health Sciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-52534 PARALLAX HEALTH SCIENCES, I
March 31, 2014	NT 10-K	- FORM NT-10K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 10, 2014	8-K	Current Report Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or o TRANSITION R Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 14, 2013	NT 10-Q	- EDVP 2013-09-30 NT-10Q Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-166487 ENDEAVOR POWER C
May 15, 2013	EX-10.31	Consulting Agreement between Endeavor Power Corporation and Capital Group Communications, Inc. dated January 10, 2013 Endeavor Power Corporation 10-Q Exhibit 10.31 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?), effective as of January 10, 2013 is entered into by and between, Endeavor Power Corporation (herein referred to as the ?Company?) and Capital Group Communications, Inc., a California corporation with principal address at 575 Bridgeway, Sausalito CA 94965 (herein referred to as the ?Consu
May 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-166487 ENDEAVOR POWER
April 16, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 o TRANSITION REPORT UNDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from o to o Commission file number 333-166487 ENDEAVOR POWER CORP
April 16, 2013	EX-99.2	2331 MILL ROAD \| SUITE 100 \| ALEXANDRIA, VA \| 22314 Marathon Patent Group, Inc (MARA.OB) Intellectual Property Division The University of Arizona Science & Technology Park 9070 S. Rita Rd #1550 Tucson, Arizona 85747 J. Michael Redmond, CEO Endeavor Power Corporation, Inc. 2 Canal Park, 5th Floor Cambridge, MA 02141 CC: Board Members Dr. Jorn Gorlach and Edward Withrow III Dear Mr. Redmond: Pursuant to your authorization, we were engaged to perform
April 1, 2013	NT 10-K	- NOTIFICATION OF LATE FILING OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): S Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: December 31, 2012 [] Trans
November 15, 2012	EX-10.23	Employment Agreement between Roth Kline, Inc. and Michael Redmond dated November 15, 2010 Exhibit 10.23 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”), dated as of November 15, 2010 (the “Effective Date”), is made by and among Joseph Michael Redmond (“Executive”) and Roth Kline, Inc. or its successor company, a Delaware corporation (the “Company”). WHEREAS, Executive will be employed by the Company as its Chief Executive Officer (CEO) and will maintain a position of Direc
November 15, 2012	EX-10.25	Supply Agreement between Parallax Diagnostics, Inc. and Meyer Stevens Group, Inc. dated July 1, 2011 Exhibit 10.25 SUPPLY AGREEMENT This Supply Agreement (the "Agreement") is entered into as of this 1st day of July 2011 (the "Effective Date"), by and between Parallax Diagnostics Ltd., Inc. a Nevada corporation with offices at 2 Canal Park Cambridge, MA (or PRLX") and Meyers Stevens Group Inc. at 7137 Telegraph Road, Montebello, California 90640 ("Supplier") (together the "Parties"). WHEREAS, Supp
November 15, 2012	EX-4.5	2010 Employee Stock Option Plan of Parallax Diagnostics, Inc, dated October 1, 2010 Exhibit 4.5 ESOP EMPLOYEE STOCK OPTION PLAN STOCK OPTION PLAN OF PARALLAX DIAGNOSTICS, INC (F/K as Parallax Kline, Inc) OCTOBER 1, 2010 Table of Contents ARTICLE 1 GENERAL 1 1.1 Purpose of Plan 1 1.2 Definitions 1 ARTICLE 2 ADMINISTRATION OF THE PLAN 4 2.1 Administration 4 2.2 Absolute Discretion 5 2.3 No Liability for Good Faith Determinations 5 2.4 No Liability of Company 5 ARTICLE 3 ELIGIBILITY
November 15, 2012	EX-2.1	Share Exchange Agreement between Endeavor Power Corporation, Endeavor Holdings, Inc. and Parallax Diagnostics, Inc. and the Parallax Shareholders dated October 1, 2012 Endeavor Power Corp 8-K Exhibit 2.1 THE SECURITIES TO WHICH THIS AGREEMENT AND PLAN OF MERGER RELATES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, AND WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURS
November 15, 2012	EX-10.29	Convertible Preferred Purchase Agreement between Parallax Diagnostics, Inc. and Huntington Chase Financial Group, LLC, dated June 17, 2011 Endeavor Power Corp 8-K Exhibit 10.29 CONVERTIBLE PREFERRED PURCHASE AGREEMENT This Convertible Preferred Stock Purchase Agreement dated June 17, 2011 is by and between: Huntington Chase Financial Group, LLC (the “Purchaser”) Parallax Diagnostics, Inc (the “Company” or “PRLX”) WHEREAS, Parallax Diagnostics, Inc. (“PRLX” “Seller”) a Nevada corporation at 2 Canal Park, 5th Floor Cambridge, MA 02141
November 15, 2012	EX-10.22	Modification to the License of Intellectual Property between Roth Kline Inc. and Montecito BioSciences, Ltd. dated September 10, 2010 Endeavor Power Corp 8-K Exhibit 10.22 MODIFICATION AGREEMENT OF THE LICENSE OF INTELLECTUAL PROPERTY THIS AGREEMENT OF THE LICENSE OF INTELLECTUAL PROPERTY (the “Agreement”) entered into on the 30th day of September 2011 (the “Effective Date”) is for the Modification of the Agreement of the License of Intellectual Property, by and between THE PARTIES: MONTECITO BIO SCIENCES, Ltd., a corporation or
November 15, 2012	EX-10.27	Consulting Agreement between Parallax Diagnostics, Inc. and Greg Suess dated July 11, 2012 Endeavor Power Corp 8-K Exhibit 10.27 CONSULTING AGREEMENT THIS AGREEMENT (the “Agreement”), is made and entered into as of this 11th day of July 2012, by and between Greg Suess, an individual, located 1126 Strandella Road, Bel Air, CA 90077(“Suess” or the “Consultant”), and Parallax Diagnostics, Ltd. 2 Canal Park, 5th Floor Cambridge, MA 02141 (the “Client” the “Company”) (together the “Parties”)
November 15, 2012	8-K	Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets, Other Events - CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2012 ENDEAVOR POWER CORP. (Exact name of Company as specified in its charter) Nevada 333-166487 N/A (State or other jurisdiction of Incorporation) (Commission File Number) (IRS Employer
November 15, 2012	EX-10.19	Assignment of Intellectual Property between Roth Kline, Inc. and Montecito BioSciences, Ltd. dated September 10, 2010 Endeavor Power Corp. 8-K AGREEMENT OF THE ASSIGNMENT OF INTELLECTUAL PROPERTY THIS AGREEMENT OF THE ASSIGNMENT OF INTELLECTUAL PROPERTY (the “Agreement”) entered into on the 10th day of September 2010 (the “Effective Date”) is for the Assignment of Intellectual Property, by and between THE PARTIES: MONTECITO BIO SCIENCES, LTD., a corporation organized and existing under the laws of the State of Ne
November 15, 2012	EX-10.24	Development and Supply Agreement between Parallax Diagnostics, Inc. and Corder Engineering, LLC dated July 1, 2011 Exhibit 10.24 DEVELOPMENT and SUPPLY AGREEMENT This Development and Supply Agreement (the “Agreement”) is entered into as of this 1st day of July 2011 (the “Effective Date”), by and between Parallax Diagnostics Ltd., Inc. a Nevada corporation with offices at 2 Canal Park Cambridge, MA 02141 (or “PRLX”) and Corder Engineering, LLC at1357 N 100 E Chesterton, IN 46304 (“Supplier”) (together the “Part
November 15, 2012	EX-10.30	Convertible Preferred Purchase Agreement between Parallax Diagnostics, Inc. and Huntington Chase Financial Group, LLC, dated September 30, 2011 Endeavor Power Corp 8-K Exhibit 10.30 CONVERTIBLE PREFERRED PURCHASE AGREEMENT This Convertible Preferred Stock Purchase Agreement dated September 30, 2011 is by and between: Huntington Chase Financial Group, LLC (the “Purchaser”) Parallax Diagnostics, Inc (the “Company” or “PRLX”) WHEREAS, Parallax Diagnostics, Inc. (“PRLX” “Seller”) a Nevada corporation at 2 Canal Park, 5th Floor Cambridge, MA 0
November 15, 2012	EX-3.3	Articles of Merger between Endeavor Power Corporation and Parallax Diagnostics, Inc. filed with Secretary of State of Nevada on November 6, 2012 Endeavor Power Corp 8-K Exhibit 3.3
November 15, 2012	EX-10.26	Consulting Agreement between Parallax Diagnostics, Inc. and Huntington Chase Financial Group, LLC dated January 2, 2012 Parallax Diagnostics-Huntington Chase Confidential Consulting Agreement Exhibit 10.

PRLX / Parallax Health Sciences Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)